NCT06191731 Kinetics of Urinary Excretion of Gadolinium Contrast Agents Used in MRI Examinations
| NCT ID | NCT06191731 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Hospitalier Régional Metz-Thionville |
| Condition | Magnetic Resonance Imaging |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2024-04-12 |
| Primary Completion | 2026-04-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2024-04-12 with a primary completion date of 2026-04-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a single-center cohort study aimed to describe the urinary excretion kinetics of gadolinium contrast agents (Gd-CAs). Patients with a prescription for injected MRI are invited to participate in the study. If they agree, blood and urine samples are collected before Gd-CAs injection, and urine samples are collected between 0- and two-and-a-half-hours post-injection of Gd-CAs.
Eligibility Criteria
Inclusion Criteria: Patients: * over 18 years of age * with a prescription for MRI with gadolinium-based contrast agents (Gd-CAs) injection validated by a radiologist * affiliated with a health insurance plan * have signed an informed consent form Exclusion Criteria: * Patients: * with known allergy to gadolinium-based contrast agents (Gd-CAs) * with known severe renal impairment (GFR \< 30 mL/min) * on dialysis * with urinary incontinence * with an ongoing urinary tract infection * under hydric or hydrosodic restriction * unable to urinate independently * Protected persons (under guardianship, curatorship or safeguard of justice) * Pregnant or breast-feeding women
Contact & Investigator
Rémi DUPRES, MD
PRINCIPAL INVESTIGATOR
CHR Metz Thionville Hopital Mercy
Frequently Asked Questions
Who can join the NCT06191731 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Magnetic Resonance Imaging. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06191731 currently recruiting?
Yes, NCT06191731 is actively recruiting participants. Contact the research team at projet-recherche-clinique@chr-metz-thionville.fr for enrollment information.
Where is the NCT06191731 trial being conducted?
This trial is being conducted at Metz, France.
Who is sponsoring the NCT06191731 clinical trial?
NCT06191731 is sponsored by Centre Hospitalier Régional Metz-Thionville. The principal investigator is Rémi DUPRES, MD at CHR Metz Thionville Hopital Mercy. The trial plans to enroll 60 participants.